Zhiyuan Vision Announces Global First Multi-Disease AI Diagnostic Software for Blindness-Causing Eye Conditions

With the release of the National Health Commission's "14th Five-Year Plan" for National Eye Health (2021-2025),Diabetic retinopathy, glaucoma, etc.Ophthalmic DiseasesHarmsHas increasingly gained people's attention.

According to relevant epidemiological statistics, currentlyFundus DiseasesHas become one of the major blinding eye diseases in China, with the number of patients with diabetic retinopathy exceeding40,000,000, The population suffering from age-related macular degeneration is on the rise due to the intensifying trend of aging; at the same time, the population affected by glaucoma is approximately20 Million.Relying onArtificial Intelligence and Telemedicine Technology, Enhance grassroots health care institutionsScreening for Fundus Diseases and GlaucomaThe ability to promote the construction of a "hierarchical diagnosis and treatment" service model, and to advance the "early screening, early diagnosis, and early treatment" of patients with fundus diseases has become an important approach in strengthening the construction of ophthalmic medical service capabilities in China's National Eye Health Plan.

The Effectiveness of Artificial Intelligence in Assisting with Ophthalmic Medical Imaging Diagnosis is Significant. This is mainly reflected in: Through training with a large number of real medical images, artificial intelligence systems can reach the film-reading level of experienced ophthalmologists. More importantly, its film-reading speed far exceeds that of humans, enabling continuous, stable, and efficient analysis of large batches of medical images. In screening scenarios such as primary healthcare institutions and endocrinology departments, artificial intelligence systems can help young doctors improve their film-reading skills, significantly enhancing the service capacity for ophthalmic screening at the grassroots level. This not only improves the time efficiency of screening but also...Breaks through geographical limitations, which can effectively solve the problem of insufficient and uneven distribution of ophthalmologists in China. The introduction of artificial intelligence can provide patients with higher quality, precise, and standardized ophthalmic diagnosis and treatment services. Moreover, these services are no longer restricted by time and location, realizing a medical service experience that is accessible anytime, anywhere, and convenient.

June 18,Vistel(hereinafter referred to as "Vistel") produced innovative products"Fundus Lesion Fundus Image Auxiliary Diagnosis Software"(EyeWisdom®MCS) has passed the review of the National Medical Products Administration,Officially Approved for NMPA Class III Medical Device Registration Certificate(State Medical Device Registration Approval 20243211109). Previously, EyeWisdom®MCS has obtained CE MDR certification and has been implemented in the markets of developed EU countries such as France and Germany. Fundus disease fundus image auxiliary diagnosis software (EyeWisdom®MCS)World's First Technology, it took 7 years from the R&D project initiation to obtaining the registration certificate, throughIndependent Patent TechnologySolved the world's难题 of identifying complex fundus lesions and can adapt to various models and different photo qualities. The product is able to accurately identify more than ten major blinding ocular diseases, such as diabetic retinopathy and glaucoma-like optic nerve changes, based on a single fundus color photograph. Compared with single-disease AI products,This software'sMulti-disease CharacteristicsMaking it truly adaptable to the complexity of populations in real clinical environments.

July 9 (Tuesday) 19:30VCBeat's Strict Selection of New Products, Issue 73, invited Sun Yuhui, founder and CEO of Vistel, Professor Chen Youxin, director of the Ophthalmology Department at Peking Union Medical College Hospital & doctoral supervisor, and Ding Dayong, co-founder and CTO of Vistel, to present."World's First AI-Assisted Diagnosis Software for Multiple Blinding Eye Diseases"Product Promotion.

The Only One in The WorldApproved by the EU CE certification,OnlyThrough"Special Review Procedure for Innovative Medical Devices"Take the lead in completingMore than 10 typesRetinal Disease Clinical Trial Registry, The Only OneOfficially Approved for NMPA Class III Medical Device Registration CertificateOphthalmology Multi-disease Auxiliary Diagnosis System.

AI analysis can be performed based on a single color fundus photograph of the posterior pole to determine the presence of abnormal lesions. It provides auxiliary diagnostic analysis for over 10 types of fundus diseases, including glaucoma, epiretinal membrane, macular hole, and age-related macular degeneration, with excellent clinical results.Can help doctors accurately diagnose blinding diseases in fundus images, empowering early screening, diagnosis, and treatment of fundus diseases and glaucoma in China.

The ProductCan be widely used in physical examination centers, primary medical institutions, and even ophthalmology.Such institutions have significantly improved the current situation of the lack of grassroots ophthalmology professionals and insufficient disease diagnostic capabilities, promoted the realization of hierarchical diagnosis and treatment, and enhanced the efficiency of diagnosis and treatment of fundus diseases in large medical institutions.

During the development of this productSupported by the Beijing Municipal Science and Technology Commission's "Collaborative Innovation in Medicine" Special Project.The special project undertaken by Peking Union Medical College Hospital and Vistel has provided a solid foundation for the smooth development and market launch of the product. From the R&D initiation to obtaining the registration certificate, it took seven years.EyeWisdom®MCSIt is the result of a high-level integration of medical research and production.Led by Professor Chen Youxin's team at Peking Union Medical College Hospital,A medical team composed of experts from Henan Provincial Eye Hospital, Beijing Tongren Hospital, and other institutions, in collaboration with the artificial intelligence research and development team led by Professor Li Xirong from Renmin University of China, worked in close cooperation and coordination to ensure the high quality and performance of this product, making it truly applicable in clinical settings.The academic innovation achievements during the product development process have also been recognized by international peers, with related papers published inNature sub-journal npj Digital Medicine and other top academic journalsUp.

1. In physical examination centers, primary medical institutions, and even ophthalmology departments, it can significantly improve the current situation of the lack of grassroots ophthalmology professionals and insufficient disease diagnostic capabilities;

2. Promote hierarchical medical treatment, enhance cooperation among doctors with different capabilities in the medical system, and improve the diagnosis and treatment efficiency of fundus diseases in large medical institutions.

3. Achieve more efficient disease management and treatment, improve the medical service level of grassroots health institutions, and enhance the overall operational efficiency of the healthcare system.

1. Ophthalmic medical AI products have truly entered the "multi-disease" era, with AI products covering major clinical diseases being a pioneering innovation in China and even globally.

2. Ophthalmology AI "Multi-disease" Product Lays Foundation, Provides Direction for Development of Other Holistic Health Products.

Scan the QR code on the poster to add the assistant and schedule a live broadcast.

Sun Yuhui

Founder and CEO of Vistel

Before founding Vistel, Sun Yuhui worked at Intel for 15 years, where he was responsible for initiating and leading Intel's global channel innovation projects. He has worked in Beijing, Hong Kong, Singapore, and other places, gaining unique insights and extensive experience in international market operations.

Sun Yuhui obtained a master's degree in computer science from Fudan University under the guidance of Professor Zhang Gendu, the chief professor of Fudan University.

Chen Youxin

Director of Ophthalmology, Peking Union Medical College Hospital, Professor, Doctoral Supervisor

Director of the Key Laboratory of Fundus Diseases, Chinese Academy of Medical Sciences

Deputy Group Leader of the National Technical Guiding Group for Blindness Prevention

Standing Committee Member of the Ophthalmology Branch of the Chinese Medical Association

President of the Ophthalmic Health Branch of the China Aging Wellness Association

Vice President of the Ophthalmology Branch of the Chinese Geriatrics Society

President of the Ophthalmology Specialist Committee of the Beijing Medical Doctor Association

Deputy Editor-in-Chief of "Chinese Journal of Ocular Fundus Diseases" and "Chinese Journal of Optometry & Ophthalmology"

《BMC Ophthalmology》Associate editor

Ding Dayong

Vistel Co-Founder, CTO

Dr. Dayong Ding has nearly 20 years of research experience in the fields of computer vision and artificial intelligence, with profound expertise in multimedia, human-computer interaction, and machine learning. He has served as a senior researcher at Intel China Research Center and as the Director of Collaborative Invention at Beijing Zhigu, and is the inventor of more than 60 patented inventions.

Ding Dayong obtained his Ph.D. from the Department of Computer Science at Tsinghua University, under the guidance of Professor Zhang Ba, the first academician of the Chinese Academy of Sciences in China's artificial intelligence field.

Vistel is a national high-tech enterprise and a Beijing-based "specialized, refined, distinctive, and innovative" enterprise that focuses on the application of artificial intelligence in the field of ophthalmic healthcare.

Since its establishment eight years ago, Vistel has been committed to providing integrated hardware and software artificial intelligence solutions for all scenarios in ophthalmic healthcare. Its professional capabilities have been recognized by high-level ophthalmology teams from renowned tertiary hospitals such as Peking Union Medical College Hospital, Tongren Hospital, Shanghai Eye Disease Prevention Institute, Zhongshan Hospital, and the First Affiliated Hospital of Zhengzhou University. It has been clinically applied in over 1,800 medical institutions across China, covering primary screening, auxiliary diagnosis, treatment, and other medical procedures for various common blinding retinal diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration, cumulatively serving more than one million patients.

Vistel has a complete and innovative R&D system with independent intellectual property rights. It has published over 40 academic papers in top-tier academic journals such as Nature's npj Digital Medicine and high-level international academic conferences like T-PAMI, ICCV, ECCV, and ACMMM. The company has obtained more than 60 software copyrights and over 20 patents.

Vistel's self-developed auxiliary diagnosis software for fundus images of diabetic retinopathy was the first to obtain China's NMPA Class III medical device certification and EU CE certification. The multi-disease fundus image auxiliary diagnosis software is the world's only system to have obtained EU CE certification, the only one to have passed the "Special Review Procedure for Innovative Medical Devices," the first to complete registration clinical trials for more than 10 types of fundus diseases, and the only officially approved NMPA Class III medical device registration certificate for an ophthalmic multi-disease auxiliary diagnosis system. Currently, the product has been commercially applied on a large scale in France, Germany, Spain, Italy, and other countries, receiving high praise from partners.

"Artery Strict Selection New Product Review" is a live broadcast column under "Artery Strict Selection" that supports the release of innovative medical products. The column's mission is to assist in the milestone release of every medical innovation product.

Scan the QR code below to contact the assistant for live broadcast reservation (if already added, please ask the assistant directly).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant to send a live broadcast screenshot, participate in the lucky draw for a chance to win [15-day trial membership of VCBeat's VBInsight].